Clinical Trial Update: PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? [Phase 3]

View source ↗

Summary

Phase 3 trial update investigating PROACT to prevent chemotherapy-related heart damage in patients with breast cancer and non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-hodgkin Lymphoma

Snippet

Sponsor: South Tees Hospitals NHS Foundation Trust | Conditions: Breast Cancer, Non Hodgkin Lymphoma | Phase 3 | Status: COMPLETED